Ravi Kant Upadhyay*

Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP, India

*Corresponding Author: Ravi Kant Upadhyay, Department of Zoology, Deen Dayal Upadhyaya Gorakhpur University, Gorakhpur, UP, India.

Received: July 12, 2021 ; Published: July 28, 2021

Abstract

Present review article describes causes of resurgence, pathogenesis and prevention of serious and potentially life-threatening bacterial diseases i.e. typhoid, cholera, tuberculosis, leptospirosis, Brucellosis, pertussis, shigellosis, leprosy, anthrax, and plague occur in human. This article high lights effect of climatic and weather conditions on vector and food-borne bacterial diseases, its various modes of transmission to humans. This article also explains effect of various toxins on body tissues, cells and organ systems that results in increase in the morbidity in patients. On one side there is a problem in treatment of bacterial diseases and safety of patients and on other side there is rising bacterial resistance to antimicrobials. Development of drug resistant biotypes of bacteria is showing high infectivity, morbidity and potentially devastating consequences of illness with high death rates. These newly resurged bacterial strains are detrimental and making heavy losses to world economy, health, education, tourism, social interaction, religion, labor, markets, transportation, and human freedom. This article emphasizes the various contributing factors which are responsible for emergence and re-emergence of bacterial diseases, and its, diagnostics, treatment and prophylactic measures for community protection.

Keywords: Bacterial Diseases; Drug Resistance; Resurgence; Pathogenesis; Prevention

References

1. Doron S and Gorbach SL. “Bacterial Infections: Overview”. International Encyclopedia of Public Health (2008): 273-282.
2. Bannister BA., et al. “Structure and classification of pathogens”. 2^nd Blackwell Science Ltd; Oxford, UK (1996): 23-34.
3. Benenson AS. “Control of Communicable Diseases Manual”. 16^th American Public Health Association; Washington, DC (1995).
4. Evans AS and Brachman PS. “Bacterial Infections of Humans: Epidemiology and Control”. 3^rd Plenum Publishing Corporation; New York (1998).
5. Dyson ZA., et al. “Antibiotic Resistance and Typhoid”. Clinical Infectious Diseases2 (2019): S165-S170.
6. Ma PY., et al. “Human Genetic Variation Influences Enteric Fever Progression”. Cells 10 (2021): 345.
7. Asadgol Z., et al. “The effect of climate change on cholera disease: The road ahead using artificial neural network”. PLoS ONE11 (2019): e0224813.
8. Olago D., et al. “Climatic, socio-economic, and health factors affecting human vulnerability to cholera in the Lake Victoria basin, East Africa. AMBIO”: A Journal of the Human Environment4 (2007): 350-358.
9. Luque Fernández MÁ., et al. “Influence of temperature and rainfall on the evolution of cholera epidemics in Lusaka, Zambia, 2003–2006: analysis of a time series”. Transactions of the Royal Society of Tropical Medicine and Hygiene 2 (2009): 137-143.
10. Semenza JC., et al. “Mapping climate change vulnerabilities to infectious diseases in Europe”. Environmental Health Perspectives3 (2011): 385-392.
11. Greer A., et al. “Climate change and infectious diseases in North America: the road ahead”. Canadian Medical Association Journal6 (2008): 715-722.
12. Mills JN., et al. “Potential influence of climate change on vector-borne and zoonotic diseases: a review and proposed research plan”. Environmental Health Perspectives11 (2010): 1507-1514.
13. Tonnang HE., et al. “Predicting and mapping malaria under climate change scenarios: the potential redistribution of malaria vectors in Africa”. Malaria Journal1 (2010): 111.
14. González C., et al. “Climate change and risk of leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species”. PLoS Neglected Tropical Diseases1 (2010): e585.
15. De Magny GC., et al. “Cholera outbreak in Senegal in 2005: was climate a factor?” PLoS One8 (2012): e44577.
16. Emch M., et al. “Seasonality of cholera from 1974 to 2005: a review of global patterns”. International Journal of Health Geographics1 (2008): 31.
17. Morens DM and Fauci AS. “Emerging Infectious Diseases: Threats to Human Health and Global Stability”. PLOS Pathogens7 (2013): e1003467.
18. Hashizume M., et al. “The effect of rainfall on the incidence of cholera in Bangladesh”. Epidemiology 1 (2008): 103-110.
19. Ruiz-Moreno D., et al. “Cholera seasonality in Madras (1901–1940): dual role for rainfall in endemic and epidemic regions”. EcoHealth 1 (2007): 52-62.
20. Hashizume M., et al. “Cholera in Bangladesh:" Climatic Components of Seasonal Variation". Epidemiology (2010): 706-710.
21. Lipp EK., et al. “Effects of global climate on infectious disease: the cholera model”. Clinical Microbiology Reviews4 (2002): 757-770.
22. Boardman BK and Satchell KJ. “Vibrio cholerae strains with mutations in an atypical type I secretion system accumulate RTX toxin intracellularly”. Journal of Bacteriology 23 (2004): 8137-8143.
23. Nicole Fogel. “Tuberculosis: A disease without boundaries”. Tuberculosis 5 (2015): 527-531.
24. Keshavjee S and Farmer P. “Tuberculosis, drug, resistance, and the history of modern medicine”. The New England Journal of Medicine 10 (2012): 931-936.
25. Prasanna A and Niranjan V. “Classification of Mycobacterium tuberculosis DR, MDR, XDR Isolates and Identification of Signature Mutation Pattern of Drug Resistance”. Bioinformation4 (2019): 261-268.
26. Solari L., et al. “Mutations in Mycobacterium tuberculosis Isolates with Discordant Results for Drug-Susceptibility Testing in Peru”. International Journal of Microbiology (2020): 8253546.
27. Nahid Payam., et al. “Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis”. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 7 (2016): e147-e195.
28. Bekale Raymonde B., et al. “Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines”. Pharmaceutical Research1 (2018): 8.
29. Berry MPR., et al. “Systems approaches to studying the immune response in tuberculosis”. Current Opinion in Immunology5 (2013): 579-587.
30. Andersen J and Woodworth S. “Tuberculosis vaccine – rethinking the current paradigm”. Trends in Immunology8 (2014): 387-395.
31. Hawn Thomas R., et al. “Tuberculosis vaccines and prevention of infection”. Microbiology and Molecular Biology Reviews: MMBR4 (2014): 650-671.
32. Sable SB., et al. “Tuberculosis Vaccine Development: Progress in Clinical Evaluation”. Clinical Microbiology Reviews1 (2019): e00100-001119.
33. Wynwood Sarah Jane., et al. “Leptospirosis from water sources”. Pathogens and Global Health7 (2014): 334-338.
34. Ko AI., et al. “Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen”. Nature Reviews Microbiology10 (2009): 736-747.
35. Julio Croda Claudio., et al. “Targeted Mutagenesis in Pathogenic Leptospira Species: Disruption of the LigB Gene Does Not Affect Virulence in Animal Models of Leptospirosis”. Infection and Immunity12 (2008): 5826-5833.
36. Lucero NE., et al. “A new variant of Brucella melitensis”. Clinical Microbiology and Infection6 (2006): 593-596.
37. Verger JM., et al. “Classification of Brucella strains isolated from mammals using DNA‐DNA hybridisation and ribotyping”. Research in Microbiology 151 (2000): 797-799.
38. Cloeckaert A., et al. “Classification of Brucella spp. isolated from marine mammals by DNA polymorphism at the omp2 locus”. Microbes and Infection 3 (2001): 729.
39. Godfroid J., et al. “From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re‐emerging zoonosis”. Veterinary Research 36 (2005): 313-326.
40. Borska K and Simkovicova M. “Studies on the circulation of Bordetella pertussis and Bordetella parapertussis in populations of children”. Journal of Hygiene, Epidemiology, Microbiology, and Immunology 16 (1972): 159-172.
41. Leber AL. “Pertussis: relevant species and diagnostic update”. Clinics in Laboratory Medicine 34 (2014): 237-255.
42. Kilgore Paul E., et al. “Pertussis: Microbiology, Disease, Treatment, and Prevention”. Clinical Microbiology Reviews3 (2016): 449-86.
43. “Diseases of the Respiratory System”. Veterinary Medicine (2017): 845.
44. Wenzel Esther Veronika., et al. “Human antibodies neutralizing diphtheria toxin in vitro and in vivo”. Scientific Reports 1001 (2020): 571.
45. Shafiee Fatemeh., et al. “Targeted Diphtheria Toxin-Based Therapy: A Review Article”. Frontiers in Microbiology 10 (2019): 2340.
46. Qiu S., et al. “Multidrug-resistant atypical variants of Shigella flexneri in China”. Emerging Infectious Diseases7 (2013): 1147-1150.
47. Sack DA., et al. “Antimicrobial resistance in shigellosis, cholera and campylobacteriosis”. (2013).
48. Van Der Ploeg CA., et al. “Laboratory protocol: Serotyping of Shigella spp”. WHO Global Foodborne Infections Network (2010).
49. Zhang W., et al. “Wide dissemination of multidrug resistant Shigella isolates in China”. Journal of Antimicrobial Chemotherapy 66 (2011): 2527-2535.
50. Mandal J., et al. “The recent trends in shigellosis: A JIPMER perspective”. Journal of Clinical and Diagnostic Research 6 (2012): 1474-1477.
51. Pazhani GP., et al. “Molecular characterization of multidrug-resistant Shigella species isolated from epidemic and endemic cases of shigellosis in India”. Journal of Medical Microbiology l57 (2008): 856-863.
52. Srinivasa H., et al. “Magnitude of drug resistant shigellosis: A report from Bangalore”. Indian Journal of Medical Microbiology 27 (2009): 358-360.
53. Taneja N. “Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigellae in India”. Journal of Clinical Microbiology 45 (2007): 678-679.
54. Divya MP., et al. “Mutations in gyrA and parC genes of Shigella flexneri 2a determining the fluoroquinolone resistance”. Indian Journal of Medical Research6 (2015): 836-838.
55. Lee Hu Suk., et al. “Seasonal and geographical distribution of bacillary dysentery (shigellosis) and associated climate risk factors in Kon Tam Province in Vietnam from 1999 to 2013”. Infectious Diseases of Poverty1 (2017): 113.
56. Silva Débora Santos da., et al. “Blood coagulation abnormalities in multibacillary leprosy patients”. PLoS Neglected Tropical Diseases3 (2018): e0006214.
57. Gaschignard Jean., et al. “Pauci- and Multibacillary Leprosy: Two Distinct, Genetically Neglected Diseases”. PLoS Neglected Tropical Diseases5 (2016): e0004345.
58. Da Silva Rocha Adalgiza., et al. “Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients”. Journal of Clinical Microbiology6 (2012): 1912-1917.
59. Noboru Nakata., et al. “Mutation Analysis of the Mycobacterium leprae folP1 Gene and Dapsone Resistance”. Antimicrobial Agents and Chemotherapy2 (2011): 762-766.
60. Se-Kon Kim., et al. “Detection of gene mutations related with drug resistance in Mycobacterium leprae from leprosy patients using Touch-Down (TD) PCR”. FEMS Immunology and Medical Microbiology1-2 (2003): 27-32.
61. Severin Paul N and Phillip A Jacobson. “Types of Disasters”. Nursing Management of Pediatric Disaster (2020): 85-197.
62. Klietmann WF and KL Ruoff. “Bioterrorism: implications for the clinical microbiologist”. Clinical Microbiology Reviews2 (2001): 364-381.
63. Finke Ernst-Jürgen., et al. “Review: The risk of contracting anthrax from spore-contaminated soil - A military medical perspective”. European Journal of Microbiology and Immunology2 (2020): 29-63.
64. Makino S., et al. “Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax”. The Journal of Infectious Diseases 186 (2002): 227-233.
65. Spencer RC. "Bacillus anthracis". Journal of Clinical Pathology3 (2003): 182-187.
66. Inglesby TV., et al. “Plague as a biological weapon: medical and public health management”. The Journal of the American Medical Association 283 (2000): 2281-2290.
67. Anderson RM and May RM. “Infectious diseases of humans: Dynamics and control”. New York: Oxford University Press (1992).
68. Ansari Issmaeel., et al. “Deliberate release: Plague - A review”. Journal of Biosafety and Biosecurity (2020): 10-22.
69. Sebbane Florent and Nadine Lemaître. “Antibiotic Therapy of Plague: A Review”. Biomolecules5 (2021): 724.
70. Quenee LE., et al. “Yersinia pestis caf1 variants and the limits of plague vaccine protection”. Infection and Immunity5 (2008): 2025-2036.
71. Cohen ML. “Epidemiology of drug resistance: Implications for a post-antimicrobial era”. Science 257 (1992): 1050-1055.
72. Gudipati Smitha., et al. “Can the One Health Approach Save Us from the Emergence and Reemergence of Infectious Pathogens in the Era of Climate Change: Implications for Antimicrobial Resistance?”. Antibiotics 9 (2020): 599.
73. Davies J and Webb V. “Antibiotic resistance in bacteria”. In: Krause RM, editor. Emerging infections”: Biomedical Research Reports. San Diego, CA: Academic Press (1998).
74. Morse S. “Factors in the emergence of infectious diseases”. Emerging Infectious Diseases 1 (1995).
75. Fauci AS. “New and reemerging diseases: the importance of biomedical research”. Emerging Infectious Diseases 3 (1998): 374-378.
76. Treffers Henry P. "Neutralizing antibody". Access Science. McGraw-Hill (2014).
77. Janeway's immunobiology (8th edition.). Garland Science (2012): 388.
78. Diphtheria antitoxin contains polyclonal antibodies against the diphtheria toxin 26.

Citation

Citation: Ravi Kant Upadhyay. “Resurgence of Bacterial Diseases, Pathogenesis, Host Immune Responses, Prevention and its Control ”. Acta Scientific Microbiology 4.8 (2021): 109-133.

Copyright

Copyright: © 2021 Ravi Kant Upadhyay. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.